Tel Aviv, Israel (August 5, 2020) – Sight Diagnostics, the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, announced today it has raised $71 million in Series D funding with participation from Koch Disruptive Technologies, Longliv Ventures and OurCrowd. This new round brings Sight’s total funding to more than $124 million and will support the expansion of Sight’s commercial operations globally and advance Sight’s R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity.

Read more here.

Source: https://blog.ourcrowd.com/sight-diagnostics-raises-71m-to-accelerate-global-expansion-of-itsfda-510k-cleared-ce-marked-finger-prick-blood-analyzer/